Zandant was saying that our most promising drug was P which it NEVER WAS. Anyone who followed this company for years would know it was the drug we knew least about and not enough of backing of trial information IMO.
BRILACIDIN was and is our most promising drug due to having it proven itself over multiple PH1,PH2a, PH2b trials across multiple applications. I have stated for a long time that B-OM will be our first to market drug with other indications following after. B is not just a one trick pony and has such a vast use to help patients.
K is our moonshot and yes it still need to be reformulated to pill form but any drug that has shown to activate the P-53 gene has value no mater what. We still have a lot of testing with it to see where it can fit in but they will find out one day.
I'm frustrated about the seeing where the money will come from but IMO we will soon find out.
News 
Market Data 
Discover 
AI
